alpha-v/beta-3 receptor antagonist/verteporfin conjugate (BMS)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namealpha-v/beta-3 receptor antagonist/verteporfin conjugate (BMS)
Drug Alias Namereceptor-targeted PDT (BMS)receptor-targeted photodynamic therapy compounds (BMS)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsMacular DegenerationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsMacular DegenerationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A